Uzm. Dr. İsmail Hakkı Akbeyaz
Is this your profile? Claim it and verify your details.
Claim profilePerson ↔ Disease
Which diseases does this doctor work on?
-
Developmental Disabilities 3 publicationsSource: OpenAlex / PubMed MeSHView publications
- Spinal Muscular Atrophies of Childhood 2 publications
Trust
Where does this information come from?
The source is stated next to each piece of information. If you see something wrong, you can suggest a correction.
- SpecialtyPaediatric Neurologysaglik.gov.trFrom source
- InstitutionMarmara Üniversitesi Pendik Eğitim ve Araştırma Hastanesisaglik.gov.trFrom source
- Area of workDevelopmental DisabilitiesExtracted from 3 publications · Model version —From source
- Publications28 publicationsOpenAlexFrom source
- ORCID0000-0001-6400-2775ORCIDFrom source
- Last synchronised5 November 2026 10:37https://marmaraeah.saglik.gov.tr/TR-1393210/doktorlarimiz.html#ismail-hakki-akbeyazsaglik.gov.tr
Scientific work
Publications on Developmental Disabilities
-
Early Childhood Obesity: Multifactorial Influences with a Prominent Familial Contribution
Journal of Clinical Research in Pediatric Endocrinology, 2026
DOI 10.4274/jcrpe.galenos.2026.2025-12-23 PMID 41837715 Open-access full textSource: OpenAlex
-
Influenza-associated neurological complications in pediatric patients: clinical characteristics, outcomes, and the neuroinfluenza severity score in the multicenter TURK-INF study
European Journal of Pediatrics, 2026
DOI 10.1007/s00431-026-07411-6 PMID 42745076 Open-access full textSource: OpenAlex
-
Expanding the clinical and molecular spectrum of NGLY1 deficiency: A multicenter cohort
Molecular Genetics and Metabolism, 2026
DOI 10.1016/j.ymgme.2026.110195 PMID 42361657 Source: OpenAlex
-
Extreme ambient temperatures and seizure outcomes in children with epilepsy: insights from a survey in Turkey
Epilepsy & Behavior, 2026
DOI 10.1016/j.yebeh.2026.110982 PMID 41797236 1 citation (OpenAlex) Source: OpenAlex
-
Identification of Cerebrotendinous Xanthomatosis in High-Risk Children Using a Suspicion Index–Based Screening Strategy
Research Square, 2026
DOI 10.21203/rs.3.rs-10809714/v1 Open-access full textSource: OpenAlex
-
1.56P Timing of therapy in sma type 1: longitudinal clinical and real-world insights
Neuromuscular Disorders, 2026
DOI 10.1016/j.nmd.2026.106641 Source: OpenAlex
-
Comparison of Nusinersen Monotherapy Versus Combination Therapy With Nusinersen and Onasemnogene Abeparvovec in Spinal Muscular Atrophy Type 1 Patients With Two SMN2 Copies: A Multicenter Study From Türkiye
Muscle & Nerve, 2026
DOI 10.1002/mus.70191 PMID 41757676 Source: OpenAlex
-
Effects of newborn screening and nusinersen on survival and functional outcomes in spinal muscular atrophy with two SMN2 copies: A nationwide multicentre real-world study from Turkey
European Journal of Paediatric Neurology, 2026
DOI 10.1016/j.ejpn.2026.08.003 PMID 42580234 Source: OpenAlex
-
1.30P Determinants of comorbidities influencing quality of life in pediatric neuropathy patients: implications for optimized follow-up strategies
Neuromuscular Disorders, 2026
DOI 10.1016/j.nmd.2026.106579 Source: OpenAlex
-
Personalized Management and Timing of Thymectomy in Juvenile Myasthenia Gravis: Insights from Routine Clinical Scale Use in a Single-Center Retrospective Cohort—A Case Series
Children, 2025
DOI 10.3390/children12101389 PMID 41153571 Open-access full textSource: OpenAlex